Although the onset and patterns of cognitive symptoms and cortical atrophy present in SPG11 patients are markedly different from those observed in AD patients, our data suggest that GSK3β over-activation may be a common molecular denominator of both diseases. This evidence concerns the gene SPG11 and Cerebral cortical atrophy.